Modified AAV Capsid Targeting Peptides for Brain Structure Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated viral vector variants lack specificity and efficiency in targeting distinct brain structures, limiting their clinical translation and therapeutic applications.
Innovation Solution
Development of modified adeno-associated virus (AAV) capsid proteins with targeting peptides that are specifically designed to target various brain structures, such as the brainstem, cerebellar cortex, and hippocampus, by inserting peptides of specific sequences flanked by linker sequences into the AAV capsid proteins, enhancing their transduction efficiency and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV capsid proteins are modified with random mutagenesis or directed evolution, then transduction efficiency may be improved, but specificity for distinct brain structures is not achieved
Solution Approach 1:
The patent applies local quality by inserting specific targeting peptides at defined positions within the AAV capsid protein sequence. Rather than random mutagenesis throughout the capsid, the invention introduces targeted local modifications at specific residues (e.g., position 590 in AAV1, position 587 in AAV2, position 588 in AAV9) to confer structure-specific targeting while preserving overall capsid function and transduction efficiency.
Solution Approach 2:
The patent uses targeting peptides as intermediary elements that mediate between the AAV capsid and specific brain structures. These peptides (3-10 amino acids in length) act as molecular bridges that recognize and bind to receptors or ligands on specific neuronal populations, enabling selective targeting of distinct brain regions including cortex, hippocampus, and striatum without compromising general transduction capability.
2Ease of manufacture
If AAV variants are developed using rational design with known capsid knowledge, then targeted changes can be made to alter transduction, but translation to clinical applications is limited
Solution Approach 1:
The patent applies parameter changes by systematically varying the amino acid sequence of targeting peptides (3-10 residues) at specific capsid positions across multiple AAV serotypes. By optimizing peptide length, composition, and flanking linker sequences (e.g., SSA-AS linkers), the invention creates a library of variants with tuned targeting properties that maintain manufacturability through rational design while achieving clinical relevance through demonstrated specificity for human brain structures.
Solution Approach 2:
The patent achieves universality by developing a platform technology that can be applied across multiple AAV serotypes (AAV1, AAV2, AAV9 and others). The same targeting peptide insertion strategy and peptide design principles can be universally applied to different capsid backgrounds, enabling broad applicability to various neurological disorders and brain regions, thereby enhancing clinical translation potential through a versatile, multi-functional approach.
3Measurement precision
If targeting peptides of 3-10 amino acids are inserted into AAV capsid proteins, then specificity for distinct brain structures is achieved, but capsid structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid modification into distinct functional segments: the native capsid protein sequence, flanking linker sequences (e.g., SSA on N-terminal side and AS on C-terminal side), and the inserted targeting peptide (3-10 amino acids). This segmented approach allows each component to be independently optimized and characterized, simplifying the overall design process despite the increased structural complexity, as each segment serves a specific function without interfering with others.
Data Source
AI summary
Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain.